Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose

Acta Derm Venereol. 2019 May 1;99(6):620-621. doi: 10.2340/00015555-3148.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antipruritics / administration & dosage*
  • Aprepitant / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Humans
  • Lymphoma, T-Cell, Cutaneous / complications
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Neurokinin-1 Receptor Antagonists / administration & dosage*
  • Pruritus / drug therapy*
  • Pruritus / etiology
  • Skin Neoplasms / complications
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Antipruritics
  • Neurokinin-1 Receptor Antagonists
  • Aprepitant